A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Amylyx Pharmaceuticals said the Food and Drug Administration approved the drug for adults with amyotrophic lateral sclerosis, or ALS, which destroys nerve cells needed for basic functions like walking, talking and swallowing. It is only the third U.S.-approved medicine for ALS.
